Dear Valued Visitor,

We have noticed that you are using an ad blocker software.

Although advertisements on the web pages may degrade your experience, our business certainly depends on them and we can only keep providing you high-quality research based articles as long as we can display ads on our pages.

To view this article, you can disable your ad blocker and refresh this page or simply login.

We only allow registered users to use ad blockers. You can sign up for free by clicking here or you can login if you are already a member.

Synthetic Biologics Inc (SYN) Jumps: Is It A Good Stock To Buy?

What do hedge funds think about Synthetic Biologics Inc (NYSEAMEX:SYN)?

As stated earlier, at the end of the first quarter of 2015, a total of four hedge funds tracked by Insider Monkey held long positions in this stock, flat over the quarter. However, the last round of 13F filings showed that two investors closed their stakes and two other funds initiated new positions during the first three months. MSDC Management, led by Marc Lisker, Glenn Fuhrman and John Phelan, is the largest shareholder of Synthetic Biologics Inc (NYSEMK:SYN) with some 3.58 million shares worth $7.85 million. It is followed by Fred Knoll’s Knoll Capital Management with 3.40 million shares valued at $7.45 million.

Among the hedge funds with new positions in Synthetic Biologics are Israel Englander’s Millennium Management and Michael Platt & William Reeves’ Bluecrest Capital Management. Millennium Management owns 42,945 shares of the biotech company and Bluecrest Capital Management’s position stands at 24,251 shares, as of the end of March. On the other hand, Jeffrey Jay and David Kroin’s Great Point Partners and Ken Griffin’s Citadel Investment Group closed their stakes during the first quarter.

It is important to note that a positive result of this clinical trial could help the shares of Synthetic Biologics gain momentum in the upcoming months. Considering its impressive share performance in 2015, we consider that the stock is a ‘Buy’.

Disclosure: None

DOWNLOAD FREE REPORT: Warren Buffett's Best Stock Picks

Let Warren Buffett, George Soros, Steve Cohen, and Daniel Loeb WORK FOR YOU.

If you want to beat the low cost index funds by 19 percentage points per year, look no further than our monthly newsletter.In this free report you can find an in-depth analysis of the performance of Warren Buffett's entire historical stock picks. We uncovered Warren Buffett's Best Stock Picks and a way to for Buffett to improve his returns by more than 4 percentage points per year.

Bonus Biotech Stock Pick: You can also find a detailed bonus biotech stock pick that we expect to return more than 50% within 12 months.
Subscribe me to Insider Monkey's Free Daily Newsletter
This is a FREE report from Insider Monkey. Credit Card is NOT required.